Tech Company M&A Transactions

Presidio Pharmaceuticals Acquisition

Presidio Pharmaceuticals was acquired by BioCryst Pharmaceuticals. The transaction was announced on 10/19/2012. Purchase price was estimated to be $101 million.

Transaction Overview

Announced On
Transaction Type
M&A Terms
The acquisition will be paid for with all stock.

Company Information

Company Status
Acquired or Merged
Mailing Address
1700 Owens St. 184
San Francisco, CA 94158
Email Address
Presidio is focused on developing novel and established therapeutic modalities and small molecule compounds for the treatment of HIV-1, HCV and other chronic virus infections.
Presidio Pharmaceuticals LinkedIn Company Profile
Social Media
Presidio Pharmaceuticals Company Twitter Account
Company News
Presidio Pharmaceuticals News
Presidio Pharmaceuticals on Facebook
Presidio Pharmaceuticals on YouTube

Management Team

Email & Social
Chief Financial Officer
Leo Redmond
  Leo Redmond LinkedIn Profile  Leo Redmond Twitter Account  Leo Redmond News  Leo Redmond on Facebook
Chief Medical Officer
Nathaniel Brown
  Nathaniel Brown LinkedIn Profile  Nathaniel Brown Twitter Account  Nathaniel Brown News  Nathaniel Brown on Facebook
Chief Scientific Officer
Richard Colonno
  Richard Colonno LinkedIn Profile  Richard Colonno Twitter Account  Richard Colonno News  Richard Colonno on Facebook
VP - Regulatory Affairs
Eric Ruby
  Eric Ruby LinkedIn Profile  Eric Ruby Twitter Account  Eric Ruby News  Eric Ruby on Facebook



Browse more venture capital transactions:

Prev: 10/19/2012: BuyerCurious venture capital transaction
Next: 10/19/2012: BloomReach venture capital transaction


Share this article


Where The Data Comes From

We do our best to report on every notable VC transaction. All VC database entries reported here are sourced from news reports and company announcements. The data is sourced from, an affiliated venture.


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities


Business Glossary